Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 3
1990 1
1993 1
1995 3
1996 1
1997 2
1998 2
1999 2
2000 3
2004 1
2006 2
2014 1
2015 1
2016 1
2017 1
2018 1
2019 2
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

28 results
Results by year
Filters applied: . Clear all
Page 1
Homocysteine as a risk factor for atherosclerosis.
Temple ME, Luzier AB, Kazierad DJ. Temple ME, et al. Among authors: kazierad dj. Ann Pharmacother. 2000 Jan;34(1):57-65. doi: 10.1345/aph.18457. Ann Pharmacother. 2000. PMID: 10669187 Review.
Metabolism and excretion of (S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies.
Sharma R, Bergman A, Litchfield J, Atkinson K, Kazierad DJ, Kalgutkar AS. Sharma R, et al. Among authors: kazierad dj. Xenobiotica. 2019 Dec;49(12):1447-1457. doi: 10.1080/00498254.2019.1581960. Epub 2019 Mar 7. Xenobiotica. 2019. PMID: 30747552 Clinical Trial.
A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus.
Bergman A, Tan B, Somayaji VR, Calle RA, Kazierad DJ. Bergman A, et al. Among authors: kazierad dj. Diabetes Res Clin Pract. 2017 Apr;126:95-104. doi: 10.1016/j.diabres.2017.01.019. Epub 2017 Feb 3. Diabetes Res Clin Pract. 2017. PMID: 28237861 Clinical Trial.
28 results